Search hospitals > Montana > Billings

Saint Vincent Healthcare

Claim this profile
Billings, Montana 59101
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
Conducts research for Cancer
264 reported clinical trials
8 medical researchers
Photo of Saint Vincent Healthcare in BillingsPhoto of Saint Vincent Healthcare in BillingsPhoto of Saint Vincent Healthcare in Billings

Summary

Saint Vincent Healthcare is a medical facility located in Billings, Montana. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Cancer and other specialties. Saint Vincent Healthcare is involved with conducting 264 clinical trials across 380 conditions. There are 8 research doctors associated with this hospital, such as Nicholas DiBella, Benjamin J. George, Marwan Massouh, and Chelsea Gawryletz, MD.

Area of expertise

1Breast Cancer
Global Leader
Saint Vincent Healthcare has run 43 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
HER2 negative
2Lung Cancer
Global Leader
Saint Vincent Healthcare has run 34 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Saint Vincent Healthcare

Lung Cancer
Ovarian Cancer
Laryngeal Cancer
Oropharyngeal Carcinoma
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Multiple Myeloma
ALK Gene Rearrangement
Chronic Lymphocytic Leukemia
Throat Cancer
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Vincent Healthcare?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security